Literature DB >> 23418005

Pilot study of quantitative analysis of background enhancement on breast MR images: association with menstrual cycle and mammographic breast density.

Anabel M Scaranelo1, Maria Claudia Carrillo, Rachel Fleming, Lindsay M Jacks, Supriya R Kulkarni, Pavel Crystal.   

Abstract

PURPOSE: To perform semiautomated quantitative analysis of the background enhancement (BE) in a cohort of patients with newly diagnosed breast cancer and to correlate it with mammographic breast density and menstrual cycle.
MATERIALS AND METHODS: Informed consent was waived after the research ethics board approved this study. Results of 177 consecutive preoperative breast magnetic resonance (MR) examinations performed from February to December 2009 were reviewed; 147 female patients (median age, 48 years; range, 26-86 years) were included. Ordinal values of BE and breast density were described by two independent readers by using the Breast Imaging Reporting and Data System lexicon. The BE coefficient (BEC) was calculated thus: (SI2 · 100/SI1) - 100, where SI is signal intensity, SI2 is the SI enhancement measured in the largest anteroposterior dimension in the axial plane 1 minute after the contrast agent injection, and SI1is the SI before contrast agent injection. BEC was used for the quantitative analysis of BE. Menstrual cycle status was based on the last menstrual period. The Wilcoxon rank-sum or Kruskal-Wallis test was used to compare quantitative assessment groups. Cohen weighted κ was used to evaluate agreement.
RESULTS: Of 147 patients, 68 (46%) were premenopausal and 79 (54%) were postmenopausal. The quantitative BEC was associated with the menstrual status (BEC in premenopausal women, 31.48 ± 20.68 [standard deviation]; BEC in postmenopausal women, 25.65 ± 16.74; P = .02). The percentage of overall BE was higher when the MR imaging was performed in women in the inadequate phase of the cycle (<35 days, not 7-14 days; mean BEC, 35.7) compared with women in the postmenopausal group (P = .001). Premenopausal women had significantly higher BEC when compared with postmenopausal women (P = .03). There was no significant difference in the percentage of BE between breast density groups.
CONCLUSION: Premenopausal women with breast cancer, and specifically women in the inadequate phase of the cycle, presented with higher quantitative BE than postmenopausal women. No association was found between BE and breast density.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23418005     DOI: 10.1148/radiol.13120121

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  14 in total

1.  Diffusion-weighted MRI: association between patient characteristics and apparent diffusion coefficients of normal breast fibroglandular tissue at 3 T.

Authors:  Elizabeth S McDonald; Jennifer G Schopp; Sue Peacock; Wendy B DeMartini; Wendy D DeMartini; Habib Rahbar; Constance D Lehman; Savannah C Partridge
Journal:  AJR Am J Roentgenol       Date:  2014-05       Impact factor: 3.959

Review 2.  Evaluation of background parenchymal enhancement on breast MRI: a systematic review.

Authors:  Bianca Bignotti; Alessio Signori; Francesca Valdora; Federica Rossi; Massimo Calabrese; Manuela Durando; Giovanna Mariscotto; Alberto Tagliafico
Journal:  Br J Radiol       Date:  2016-12-07       Impact factor: 3.039

3.  Comparison of Background Parenchymal Enhancement at Contrast-enhanced Spectral Mammography and Breast MR Imaging.

Authors:  Julie Sogani; Elizabeth A Morris; Jennifer B Kaplan; Donna D'Alessio; Debra Goldman; Chaya S Moskowitz; Maxine S Jochelson
Journal:  Radiology       Date:  2016-07-04       Impact factor: 11.105

Review 4.  Background parenchymal enhancement on breast MRI: A comprehensive review.

Authors:  Geraldine J Liao; Leah C Henze Bancroft; Roberta M Strigel; Rhea D Chitalia; Despina Kontos; Linda Moy; Savannah C Partridge; Habib Rahbar
Journal:  J Magn Reson Imaging       Date:  2019-04-19       Impact factor: 4.813

5.  Impact of background parenchymal enhancement levels on the diagnosis of contrast-enhanced digital mammography in evaluations of breast cancer: comparison with contrast-enhanced breast MRI.

Authors:  Sachiko Yuen; Shuichi Monzawa; Ayako Gose; Seiji Yanai; Yoshihiro Yata; Hajime Matsumoto; You Ichinose; Takashi Tashiro; Kazuhiko Yamagami
Journal:  Breast Cancer       Date:  2022-02-26       Impact factor: 4.239

6.  Assessment of Background Parenchymal Enhancement and Lesion Kinetics in Breast MRI of BRCA 1/2 Mutation Carriers Compared to Matched Controls Using Quantitative Kinetic Analysis.

Authors:  Alana A Lewin; Sungheon Gene Kim; James S Babb; Amy N Melsaether; Jason McKellop; Melanie Moccaldi; Ana Paula Klautau Leite; Linda Moy
Journal:  Acad Radiol       Date:  2016-01-07       Impact factor: 3.173

7.  Influence of Menstrual Cycle Timing on Screening Breast MRI Background Parenchymal Enhancement and Diagnostic Performance in Premenopausal Women.

Authors:  Brian N Dontchos; Habib Rahbar; Savannah C Partridge; Constance D Lehman; Wendy B DeMartini
Journal:  J Breast Imaging       Date:  2019-06-11

8.  Analysis of background parenchymal echogenicity on breast ultrasound: Correlation with mammographic breast density and background parenchymal enhancement on magnetic resonance imaging.

Authors:  Kyung Hee Ko; Hae Kyoung Jung; Inwha Kim
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

9.  Correlation Between Mammographic Breast Density, Breast Tissue Type in Ultrasonography, Fibroglandular Tissue, and Background Parenchymal Enhancement in Magnetic Resonance Imaging.

Authors:  Afsaneh Alikhassi; Seyedeh Nooshin Miratashi Yazdi; Hedieh Akbari; Sona Akbari Kia; Masoud Baikpour
Journal:  Breast Cancer (Auckl)       Date:  2018-04-18

10.  Prediction of background parenchymal enhancement on breast MRI using mammography, ultrasonography, and diffusion-weighted imaging.

Authors:  Akiko Kawamura; Hiroko Satake; Satoko Ishigaki; Mitsuru Ikeda; Reiko Kimura; Kazuhiro Shimamoto; Shinji Naganawa
Journal:  Nagoya J Med Sci       Date:  2015-08       Impact factor: 1.131

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.